A network meta-analysis on the efficacy of 5-aminosalicylates, immunomodulators and biologics for the prevention of postoperative recurrence in Crohn's disease

International Journal of Surgery

Volumn 12, Issue 5, 2014, Pages 516-522

  Yang, Zhiping ^a   Ye, Xiaofei ^b   Wu, Qiong ^a   Wu, Kaichun ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

5 Aminosalicylates; 5 ASA; Biologics; CD; CI; CrI; Crohn's disease; Immunomodulators; Network meta analysis; OR; TNF

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PLACEBO; IMMUNOLOGIC FACTOR;

ARTICLE; BAYES THEOREM; COMPARATIVE STUDY; CROHN DISEASE; DRUG EFFICACY; ENDOSCOPY; HUMAN; INCIDENCE; META ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; BIOLOGICAL THERAPY; CLINICAL FEATURE; COCHRANE LIBRARY; COMPARATIVE EFFECTIVENESS; DISEASE ASSOCIATION; EMBASE; EVIDENCE BASED PRACTICE; GASTROINTESTINAL ENDOSCOPY; IMMUNOMODULATION; MEDLINE; POSTOPERATIVE COMPLICATION; RECURRENT DISEASE; RELAPSE; RISK REDUCTION;

BIOLOGICAL PRODUCTS; CROHN DISEASE; HUMANS; IMMUNOLOGIC FACTORS; MESALAMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TREATMENT OUTCOME;

EID: 84900030448     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2014.02.010     Document Type: Article

References (40)

1. Swoger J.M., Regueiro M. Preventive therapy in postoperative Crohn's disease. Current Opinion in Gastroenterology 2010, 26:337-343.
2. van Loo E.S., Dijkstra G., Ploeg R.J., Nieuwenhuijs V.B. Prevention of postoperative recurrence of Crohn's disease. Journal of Crohn's and Colitis 2012, 6:637-646.
3. Buisson A., Chevaux J.B., Allen P.B., Bommelaer G., Peyrin-Biroulet L. Review article: the natural history of postoperative Crohn's disease recurrence. Alimentary Pharmacology & Therapeutics 2012, 35:625-633.
4. Sorrentino D. State-of-the-art medical prevention of postoperative recurrence of Crohn's disease. Nature Reviews Gastroenterology & Hepatology 2013, 10:413-422.
5. Hashash J.G., Regueiro M.D. The evolving management of postoperative Crohn's disease. Expert Review of Gastroenterology & Hepatology 2012, 6:637-648.
6. Yamamoto T., Watanabe T. Strategies for the prevention of postoperative recurrence of Crohn's disease. Colorectal Disease 2013, 15:1471-1480.
7. Doherty G., Bennett G., Patil S., Cheifetz A., Moss A.C. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database of Systematic Reviews 2009, 7:CD006873.
8. Moss A.C. Prevention of postoperative recurrence of Crohn's disease: what does the evidence support?. Inflammatory Bowel Diseases 2013, 19:856-859.
9. Ford A.C., Khan K.J., Talley N.J., Moayyedi P. 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. American Journal of Gastroenterology 2011, 106:413-420.
10. Peyrin-Biroulet L., Deltenre P., Ardizzone S., et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. American Journal of Gastroenterology 2009, 104:2089-2096.
11. Doherty G.A., Bennett G.C., Cheifetz A.S., Moss A.C. Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. Alimentary Pharmacology & Therapeutics 2010, 31:802-809.
12. Rahimi R., Nikfar S., Rahimi F., et al. Ameta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Digestive Diseases and Sciences 2008, 53:2524-2531.
13. Hellers G., Cortot A., Jewell D., et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology 1999, 116:294-300.
14. Ewe K., Bottger T., Buhr H.J., Ecker K.W., Otto H.F. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group. European Journal of Gastroenterology & Hepatology 1999, 11:277-282.
15. Colombel J.F., Rutgeerts P., Malchow H., et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 2001, 49:42-46.
16. Buisson A., Chevaux J.B., Bommelaer G., Peyrin-Biroulet L. Diagnosis, prevention and treatment of postoperative Crohn's disease recurrence. Digestive and Liver Disease 2012, 44:453-460.
17. Trelle S., Reichenbach S., Wandel S., et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011, 342:c7086.
18. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996, 17:1-12.
19. Gross J.L., Kramer C.K., Leitao C.B., et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Annals of Internal Medicine 2011, 154:672-679.
20. Tang D.H., Malone D.C. Anetwork meta-analysis on the efficacy of serotonin type 3 receptor antagonists used in adults during the first 24 hours for postoperative nausea and vomiting prophylaxis. Clinical Therapeutics 2012, 34:282-294.
21. Armuzzi A., Felice C., Papa A., et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. Journal of Crohn's and Colitis 2013, 7:e623-e629.
22. Regueiro M., Schraut W., Baidoo L., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009, 136:441-450.e1. quiz 716.
23. Reinisch W., Angelberger S., Petritsch W., et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010, 59:752-759.
24. Caprilli R., Cottone M., Tonelli F., et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Alimentary Pharmacology & Therapeutics 2003, 17:517-523.
25. Manosa M., Cabre E., Bernal I., et al. Addition of metronidazole to azathioprine for the prevention of postoperative recurrence of Crohn's disease: a randomized, double-blind, placebo-controlled trial. Inflammatory Bowel Diseases 2013, 19:1889-1895.
26. Ardizzone S., Maconi G., Sampietro G.M., et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004, 127:730-740.
27. Brignola C., Cottone M., Pera A., et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology 1995, 108:345-349.
28. Caprilli R., Andreoli A., Capurso L., et al. Oral mesalazine (5-aminosalicylic acid; asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology & Therapeutics 1994, 8:35-43.
29. D'Haens G.R., Vermeire S., Van Assche G., et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008, 135:1123-1129.
30. Florent C., Cortot A., Quandale P., et al. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology & Hepatology 1996, 8:229-233.
31. Hanauer S.B., Korelitz B.I., Rutgeerts P., et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004, 127:723-729.
32. Herfarth H., Tjaden C., Lukas M., et al. Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease. Gut 2006, 55:1525-1526.
33. Lochs H., Mayer M., Fleig W.E., et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000, 118:264-273.
34. McLeod R.S., Wolff B.G., Steinhart A.H., et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995, 109:404-413.
35. Savarino E., Bodini G., Dulbecco P., et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology 2013, 108:1731-1742.
36. Yoshida K., Fukunaga K., Ikeuchi H., et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflammatory Bowel Diseases 2012, 18:1617-1623.
37. Sutherland L.R., Martin F., Bailey R.J., et al. Arandomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1997, 112:1069-1077.
38. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99:956-963.
39. Terdiman J.P. Prevention of postoperative recurrence in Crohn's disease. Clinical Gastroenterology and Hepatology 2008, 6:616-620.
40. Regueiro M., El-Hachem S., Kip K.E., et al. Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease. Digestive Diseases and Sciences 2011, 56:3610-3615.